Therapeutics Company Announces Clinical Trial Results For Glioblastoma Treatment
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma.
Disclaimer: The information contained in this article is based on publicly available data from the clinical trial results and announcements made by Kazia Therapeutics Limited. It is intended for informational purposes only and should not be construed as medical advice. Always consult with a healthcare professional for medical gui…